Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs

Ferdinando Pucci; Lisa M Coussens

doi:10.1016/j.ccell.2021.09.009

Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs

Cancer Cell. 2021 Oct 11;39(10):1300-1302. doi: 10.1016/j.ccell.2021.09.009.

Authors

Ferdinando Pucci¹, Lisa M Coussens²

Affiliations

¹ Department of Otolaryngology, Head, and Neck Surgery, Oregon Health and Science University, 2720 South Moody Avenue, Mail Code: KR-CDCB, Portland, OR 97201, USA; Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, 2720 South Moody Avenue, Mail Code: KR-CDCB, Portland, OR 97201, USA; Knight Cancer Institute, Oregon Health and Science University, 2720 South Moody Avenue, Mail Code: KR-CDCB, Portland, OR 97201, USA. Electronic address: pucci@ohsu.edu.
² Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, 2720 South Moody Avenue, Mail Code: KR-CDCB, Portland, OR 97201, USA; Knight Cancer Institute, Oregon Health and Science University, 2720 South Moody Avenue, Mail Code: KR-CDCB, Portland, OR 97201, USA. Electronic address: coussenl@ohsu.edu.

PMID: 34637745
DOI: 10.1016/j.ccell.2021.09.009

Abstract

Functionally significant proteins expressed by tumor macrophages have emerged as promising anti-cancer targets. In this issue of Cancer Cell, Sun et al. identify two FDA-approved agents that together safely reprogram tumor macrophages into potent anti-tumor effectors, demonstrating the power of engaging both immune system arms to fight cancer.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Humans
Macrophages
Neoplasms* / drug therapy

Substances

Antineoplastic Agents